Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yangxue Runmu prescription
- Development stage
- Phase 1
- Lead developer
- Eye Hospital, China Academy of Chinese Medical Sciences
- Administration
- Oral
01
Overview
Yangxue Runmu prescription is an oral Traditional Chinese Medicine formulation currently undergoing a multi-center clinical study for the treatment of moderate to severe dry eye. It is administered orally in conjunction with 0.1% sodium hyaluronate eye drops.
- Other names
- 养血润目方
Beyond the preview
Go deeper on Yangxue Runmu prescription.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yangxue Runmu prescription.